Navigating Shifts in CDMO-Pharma Relations: Trends and Implications

Navigating Shifts in CDMO-Pharma Relations: Trends and Implications

Tuesday, October 8, 2024 11:35 AM to 12:30 PM · 55 min. (Europe/Madrid)
Hall 5 - 5B49
Manufacturing 5.0
Manufacturing

Information

The recent acquisition of Catalent is driving significant transformation in the CDMO space within the pharmaceutical landscape. This shift has led CDMOs to expand beyond manufacturing, incorporating development services into their offerings. This evolution is redefining their role in the supply chain, providing integrated solutions that boost efficiency and foster innovation. At the same time, larger pharmaceutical companies entering the CDMO sector are changing market dynamics, increasing competition, and diversifying service offerings.

  • Why traditional CDMOs are broadening their scope by taking on development roles alongside manufacturing, reshaping their role within the pharmaceutical supply chain.
  • Assessing the impact of larger pharmaceutical companies entering the CDMO sector, and the resultant shifts in market dynamics, competition, and service offerings.
  • Reviewing the evolving relationships between CDMOs and Pharma, and what it means changing landscape.
Thermo Fisher Scientific7B18Thermo Fisher Scientific provides industry-leading pharma services solutions for drug development, clinical trial logistics, and commercial manufacturing through our Patheon brand. We partner with customers in the pharmaceutical, biotech, and life science industries as their trusted CDMO to deliver medicine to patients faster. We believe that doing this successfully not only requires science, technology, and world-class expertise, but also requires a strategic partnership - bonded by key elements such as trust, communication and collaboration. We embed these elements into every operation, interaction, and step in the drug development journey. With more than 60 locations around the world, we are committed to providing Accelerator(TM) Drug Development, 360˚ CDMO and CRO solutions, to support our customers' aspirations to get treatments to patients, faster. Our pharma services include API, biologics, cell therapy, viral vectors, formulation, clinical trials solutions, logistics services, commercial manufacturing, and packaging. We couple our scientific and technical excellence in all areas with a strategic partnership, to provide customers of all sizes access to a global network of facilities and dedicated experts across the Americas, Europe, Asia, and Australia. At Thermo Fisher Scientific, we understand that developing novel therapies and moving them from discovery to patients is a complex, high-risk process. Every customer has different needs, and every newly discovered drug has a unique pathway to reach the market. As a global, full-service CDMO and CRO partner, we help our partners bring innovative molecules and life-changing therapies to market as efficiently and safely as possible.

Registered attendees

Angela Vollstedt
Angela Vollstedt
Global Director, Cell & Gene Therapies Portfolio ManagementNovartis
Bernardo Estupiñán Gaisbauer
Bernardo Estupiñán Gaisbauer
Managing PartnerCDMO Advisor
Kaushik Datta
Kaushik Datta
Former VP, Head of North America Contract Manufacturing OperationsHaleon plc

Log in